This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Klotz, L. Search for Related Content PubMed PubMed Citation Articles by Klotz, L.

Active Surveillance for Prostate Cancer: For Whom?

Laurence Klotz

From the University of Toronto, Division of Urology, Sunnybrook & Women's College Health Sciences Centre, Toronto, Ontario, Canada

Address reprint requests to Laurence Klotz, University of Toronto Chief, Division of Urology, Sunnybrook & Women's College Health Sciences Centre, 2075 Bayview Avenue # MG 408, Toronto, Ontario M4N 3M5 Canada; e-mail: laurence.klotz{at}sw.ca.

Prostate-specific antigen (PSA) –based prostate cancer screening results in the diagnosis of prostate cancer in many men who are not destined to have clinical progression during their lifetime. Good-risk prostate cancer, defined as a Gleason score of 6 or less, PSA < 10, and T1c to T2a, now constitutes 50% of newly diagnosed prostate cancer. In most of these patients, the disease is indolent and slow growing. The challenge is to identify those patients who are unlikely to experience significant progression while offering radical therapy to those who are at risk. The approach to favorable-risk prostate cancer described in this article uses estimation of PSA doubling time (PSA DT) to stratify patients according to the risk of progression. Patients who select this approach are managed initially with active surveillance. Those who have a PSA DT of 3 years or less (based on a minimum of three determinations over 6 months) are offered radical intervention. The remainder are closely monitored with serial PSA and periodic prostate rebiopsies (at 2, 5, and 10 years). In this series of 299 patients, the median DT was 7 years. Forty-two percent had a PSA DT > 10 years, and 20% had a PSA DT > 100 years. The majority of patients on this study remain under surveillance. The approach of active surveillance with selective delayed intervention based on PSA DT represents a practical compromise between radical therapy for all (which results in overtreatment for patients with indolent disease) and watchful waiting with palliative therapy only (which results in undertreatment for those with aggressive disease).

Author's disclosures of potential conflicts of interest are found at the end of this article.

This article has been cited by other articles:

				M. J. Barry, D. S. Kaufman, and C.-L. Wu Case 15-2008 -- A 55-Year-Old Man with an Elevated Prostate-Specific Antigen Level and Early-Stage Prostate Cancer N. Engl. J. Med., May 15, 2008; 358(20): 2161 - 2168. [Full Text] [PDF]

				P. C. Walsh, T. L. DeWeese, and M. A. Eisenberger Localized Prostate Cancer N. Engl. J. Med., December 27, 2007; 357(26): 2696 - 2705. [Full Text] [PDF]

				J A. Lane, J. Howson, J. L Donovan, J. R Goepel, D. J Dedman, L. Down, E. L Turner, D. E Neal, and F. C Hamdy Detection of prostate cancer in unselected young men: prospective cohort nested within a randomised controlled trial BMJ, December 1, 2007; 335(7630): 1139 - 1139. [Abstract] [Full Text] [PDF]

				K. Fizazi The role of Src in prostate cancer Ann. Onc., November 1, 2007; 18(11): 1765 - 1773. [Abstract] [Full Text] [PDF]

				A. B Rajput, M. A Miller, A. De Luca, N. Boyd, S. Leung, A. Hurtado-Coll, L. Fazli, E. C Jones, J. B Palmer, M. E Gleave, et al. Frequency of the TMPRSS2:ERG gene fusion is increased in moderate to poorly differentiated prostate cancers J. Clin. Pathol., November 1, 2007; 60(11): 1238 - 1243. [Abstract] [Full Text] [PDF]

				D. S. Kaufman, W. S. McDougal, A. L. Zietman, and R. H. Young Case 18-2007 -- A 54-Year-Old Man with Early-Stage Prostate Cancer N. Engl. J. Med., June 14, 2007; 356(24): 2515 - 2520. [Full Text] [PDF]

				D. E. Bailey Jr and M. Wallace Critical Review: Is Watchful Waiting a Viable Management Option for Older Men With Prostate Cancer? American Journal of Men's Health, March 1, 2007; 1(1): 18 - 28. [Abstract] [PDF]

				M. S. Litwin and D. C. Miller Treating Older Men With Prostate Cancer: Survival (or Selection) of the Fittest? JAMA, December 13, 2006; 296(22): 2733 - 2734. [Full Text] [PDF]

				D. C. Miller, S. B. Gruber, B. K. Hollenbeck, J. E. Montie, and J. T. Wei Incidence of initial local therapy among men with lower-risk prostate cancer in the United States. J Natl Cancer Inst, August 16, 2006; 98(16): 1134 - 1141. [Abstract] [Full Text] [PDF]

				E. J. Small and E. A. Klein Challenges and Future Directions in the Prevention and Management of Prostate Cancer J. Clin. Oncol., November 10, 2005; 23(32): 8143 - 8145. [Full Text] [PDF]